Functional imaging of the pancreas: The role of [18F]fluoro-L- DOPA PET in the diagnosis of hyperinsulinism of infancy

Endocrine Development

Volumn 12, Issue , 2007, Pages 55-66

  Ribeiro, M ^a   Boddaert, N ^b   Delzescaux, T ^a   Valayannopoulos, V ^b   Bellanne Chantelot C ^b   Jaubert, F ^b   Verkarre, V ^b   Nihoul Fekete C ^b   Brunelle, F ^b   Lonlay, P ^b  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; FLUORINE; FLUORODOPA F 18; UNCLASSIFIED DRUG;

ARTICLE; FEMALE; HUMAN; HYPERINSULINISM; INFANT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; SCINTISCANNING;

CHILD, PRESCHOOL; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; HYPERINSULINISM; INFANT; MAGNETIC RESONANCE IMAGING; MALE; PANCREAS; POSITRON-EMISSION TOMOGRAPHY;

EID: 38449117288     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000109605     Document Type: Conference Paper

References (60)

1. Rahier J, Falt K, Muntefering H, Becker K, Gepts W, Falkmer S: The basic structural lesion of persistent neonatal hypoglycemia with hyperinsulinism: deficiency of pancreatic D cells or hyperactivity of B cells? Diabetologia 1984;26:282-289.
2. Goossens A, Gepts W, Saudubray JM, Bonnefont JP, Nihoul-Fekete, Heitz PU, Kloppel G: Diffuse and focal nesidioblastosis. A clinicopathological study of 24 patients with persistent neonatal hyperinsulinemic hypoglycemia. Am J Surg Pathol 1989;13:766-775.
3. Sempoux C, Guiot Y, Lefevre A, Nihoul-Fékété C, Jaubert F, Saudubray JM, Rahier J: Neonatal hyperinsulinemic hypoglycemia: heterogeneity of the syndrome and keys for differential diagnosis. J Clin Endocrinol Metab 1988;83:1455-1461.
4. Menni F, De Lonlay P, Sevin C, Touati G, Peigne C, Barbier V, Nihoul-Fekete C, Saudubray JM, Robert JJ: Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics 2001;107:476-479.
5. De Lonlay-Debeney P, Poggi-Travert F, Fournet JC, Sempoux C, Vici CD, Brunelle F, Touati G, Rahier J, Junien C, Nihoul-Fekete C, Robert JJ, Saudubray JM: Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 1999;340:1169-1175.
6. Stanley CA: Hyperinsulinism in infants and children. Pediatr Clin North Am 1997;44:363-374.
7. Aynsley-Green A, Polak JM, Bloom SR, Gough MH, Keeling J, Ashcroft SJ, Turner RC, Baum JD: Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycaemia. Arch Dis Child 1981;56:496-508.
8. Finegold DN, Stanley CA, Baker L: Glycemic response to glucagon during fasting hypoglycemia: an aid in the diagnosis of hyperinsulinism. J Pediatr 1980;96:257-259.
9. Hirsch HJ, Loo S, Evans N, Crigler JF, Filler RM, Gabbay KH: Hypoglycemia of infancy and nesidioblastosis. Studies with somatostatin. N Engl J Med 1977;296:1323-1326.
10. Glaser B, Hirsch HJ, Landau H: Persistent hyperinsulinemic hypoglycemia of infancy: long-term octreotide treatment without pancreatectomy. J Pediatr 1993;123:644-650.
11. Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA: Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993;123:637-643.
12. De Lonlay P, Fournet JC, Touati G, Groos MS, Martin D, Sevin C, Delagne V, Mayaud C, Chigot V, Sempoux C, Brusset MC, Laborde K, Bellane-Chantelot C, Vassault A, Rahier J, Junien C, Brunelle F, Nihoul-Fekete C, Saudubray JM, Robert JJ: Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases. Eur J Pediatr 2002;161:37-48.
13. Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J: Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995;268:426-429.
14. Nestorowicz A, Wilson BA, Schoor KP, Inoue H, Glaser B, Landau H, et al: Mutations in the sulfonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Hum Mol Genet 1996;5:1813-1822.
15. De Lonlay P, Fournet JC, Rahier J, Gross-Morand MS, Poggi-Travert F, Foussier V, Bonnefont JP, Brusset MC, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C: Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. J Clin Invest 1997;100:802-807.
16. Verkarre V, Fournet JC, De Lonlay P, Gross-Morand MS, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C: Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest 1998;102:1286-1291.
17. Fournet JC, Mayaud C, De Lonlay P, Gross-Morand MS, Verkarre V, Castanet M, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C: Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in ABCC8 or KCNJ11. Am J Pathol 2001;158:2177-2184.
18. De Lonlay P, Simon A, Galmiche-Rolland L, Giurgea I, Verkarre V, Aigrain Y, Santiago-Ribeiro MJ, Polak M, Robert JJ, Bellanne-Chantelot, Brunelle F, Nihoul-Fekete C, Jaubert F: Neonatal hyperinsulinism: clinicopathologic correlation. Hum Pathol 2007;38:387-399.
19. De Lonlay P, Benelli C, Fouque F, Ganguly A, Aral B, Dionisi-Vici C, Touati G, Heinrichs C, Rabier D, Kamoun P, Robert JJ, Stanley C, Saudubray JM: Hyperinsulinism and hyperammonemia syndrome: report of twelve unrelated patients. Pediatr Res 2001;50:353-357.
20. Filler RM, Weinberg MJ, Cutz E, Wesson DE, Ehrlich RM: Current status of pancreatectomy for persistent idiopathic neonatal hypoglycemia due to islet cell dysplasia. Prog Pediatr Surg 1991;26:60-75.
21. Fékété CN, De Lonlay P, Jaubert F, Rahier J, Brunelle F, Saudubray: The surgical management of congenital hyperinsulinemic hypoglycemia in infancy. J Pediatr Surg 2004;39:267-269.
22. Thornton PS, MacMullen C, Ganguly A, Ruchelli E, Steinkrauss L, Crane A, Aguilar-Bryan L, Stanley CA: Clinical and molecular characterization of a dominant form of congenital hyperinsulinism caused by a mutation in the high-affinity sulfonylurea receptor. Diabetes 2003;52:2403-2410.
23. Glaser B, Ryan F, Donath M, Landau H, Stanley CA, Baker L, Barton, Thornton PS: Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene. Diabetes 1999;48:1652-1657.
24. Sempoux C, Guiot Y, Dahan K, Moulin P, Stevens M, Lambot V, de Lonlay P, Fournet JC, Junien C, Jaubert F, Nihoul-Fekete C, Saudubray JM, Rahier J: The focal form of persistent hyperinsulinemic hypoglycemia of infancy: morphological and molecular studies show structural and functional differences with insulinoma. Diabetes 2003;52:784-794.
25. De Lonlay P, Giurgea I, Sempoux C, Touati G, Jaubert F, Rahier J, Ribeiro M, Brunelle F, Nihoul-Fekete C, Robert JJ, Saudubray JM, Stanley C, Bellanne-Chantelot C: Dominantly inherited hyper - insulinaemic hypoglycaemia. J Inherit Metab Dis 2005;28:267-276.
26. Thomas PM, Cote GJ, Wohllk N, Mathew PM, Gagel RF: The molecular basis for familial persistent hyperinsulinemic hypoglycemia of infancy. Proc Assoc Am Physicians 1996;108:14-19.
27. Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko HL, Rahier J, Vauhkonen I, Kere J, Laakso M, Ashcroft F, Otonkoski T: Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest 2000;106:897-906.
28. Glaser B, Kesaven P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matschinsky FM, Herold KC: Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998;338:226-230.
29. Stanley CA, Lieu YK, Hsu BY, Burlina AB, Greenberg CR, Hopwood NJ, Perlman K, Rich BH, Zammarchi E, Poncz M: Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med 1998;338:1352-1357.
30. Clayton PT, Eaton S, Aynsley-Green A, Edginton M, Hussain K, Krywawych S, Datta V, Malingre HE, Berger R, van den Berg IE: Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. J Clin Invest 2001;108:457-465.
31. Brunelle F, Negre V, Barth MO, Fekete CN, Czernichow P, Saudubray JM, Kuntz F, Tach T, Lallemand D: Pancreatic venous samplings in infants and children with primary hyperinsulinism. Pediatr Radiol 1989;19:100-103.
32. Dubois J, Brunelle F, Touati G, Sebag G, Nuttin C, Thach T, Nihoul-Fekete C, Rahier J, Saudubray JM: Hyperinsulinism in children: diagnostic value of pancreatic venous sampling correlated with clinical, pathological and surgical outcome in 25 cases. Pediatr Radiol 1995;25:512-516.
33. Chigot V, De Lonlay P, Nassogne MC, Laborde K, Delagne V, Fournet JC, Nihoul-Fékété C, Saudubray JM, Brunelel F: Pancreatic arterial calcium stimulation in the diagnosis and localisation of persistent hyperinsulinemic hypoglycaemia of infancy. Pediatr Radiol 2001;31:650-655.
34. Giurgea I, Laborde K, Touati G, Bellanne-Chantelot C, Nassogne MC, Sempoux C, Jaubert F, Khoa N, Chigot V, Rahier J, Brunelle F, Nihoul-Fékété C, Dunne MJ, Stanley C, Saudubray JM, Robert JJ, de Lonlay P: Acute insulin responses to calcium and tolbutamide do not differentiate focal from diffuse congenital hyperinsulinism. J Clin Endocrinol Metab 2004;89:925-929.
35. Stanley CA, Thornton PS, Ganguly A, MacMullen C, Underwood P, Bhatia P, Steinkrauss L, Wanner L, Kaye R, Ruchelli E, Suchi M, Adzick NS: Preoperative evaluation of infants with focal or diffuse congenital hyperinsulinism by intravenous acute insulin response tests and selective pancreatic arterial calcium stimulation. J Clin Endocrinol Metab 2004;89:288-296.
36. Lemmer K, Ahnert-Hilger G, Hopfner M, et al: Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci 2002;71:667-678.
37. Rodriguez MJ, Saura J, Finch CC, Mahy N, Billet EE: Localization of monoamine oxidase A and B in human pancreas, thyroid and adrenal glands. J Histochem Cytochem 2000;48:147-151.
38. 11C-harmine. Nucl Med Biol 2003;30:669-679.
39. Oei HK, Gazdar AF, Minna JD, Weir GC, Baylin SB: Clonal analysis of insulin and somatostatin secretion and L-dopa decarboxylase expression by a rat islet cell tumor. Endocrinology 1983;112:1070-1075.
40. Lindstrom P: Aromatic-L-amino-acid decarboxylase activity in mouse pancreatic islets. Biochim Biophys Acta 1986;884:276-281.
41. Borelli MI, Villar MJ, Orezzoli A, Gagliardino JJ: Presence of DOPA decarboxylase and its localisation in adult rat pancreatic islet cells. Diabetes Metab 1997;23:161-163.
42. Oei HK, De Jong M, Krenning EP: Gastroenteropancreatic neuroendocrine tumors; in Feinendegen LE, Shreeve WW, Eckelman WC, Bahk YW, Wagner HN (eds): Molecular Nuclear Medicine. Heidelberg, Springer, 2003, pp 385-397.
43. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71.
44. 18F DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220:373-380.
45. 18F DOPA wholebody PET - initial results. Radiology 2002;222:507-512.
46. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 2003;30:689-694.
47. 18F-fluoro-L-DOPA. J Nucl Med 2005;46:560-566.
48. 18F]fluoro-L-DOPA positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion. J Clin Endocrinol Metab 2006;291:933-940.
49. 18F]fluoro- L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur J Nucl Med Mol Imaging, in press.
50. 18F]Fluoro-L-DOPA by radiofluorodestannylation: a short and simple synthesis of a new labelling precursor. J Labelled Comp Radiopharm 1998;XLI:105-114.
51. Wells WM, Viola PV, Atsumi H, Nakajima S, Kikinis R: Multi-modal volume registration by maximization of mutual information. Med Image Anal 1996;1:35-51.
52. Maes F, Collignon A, Vandermeulen D, Marechal G, Suetens R: Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 1997;16:187-198.
53. Pluim JPW, Maintz JBA, Viergever MA: Mutual-information-based registration of medical images: a survey. IEEE Trans Med Imaging 2003;22:986-1004.
54. Maintz J, Viergever M: A survey for medical image registration. Med Image Anal 1998;2:1-36.
55. 18F-FDG PET/clinical value in pancreatic lesions - A prospective study with 104 patients. J Nucl Med 2004;45:1279-1286.
56. 18F-fluodopa PET scan. J Pediatr 2007;150:140-145.
57. 18F]-DOPA positron emission tomography. Diabetes 2006;55:13-18.
58. Asplin CM, Paquette TL, Palmer JP: In vivo inhibition of glucagon secretion by paracrine beta cell activity in man. J Clin Invest 1981;68:314-318.
59. Moens K, Berger V, Ahn JM, Van Schravendijk C, Hruby VJ, Pipeleers D, Schuit F: Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic betacells. Diabetes 2002;51:669-675.
60. Hussain K, Bryan J, Christesen HT, Brusgaard K, Aguilar-Bryan L: Serum glucagon counterregulatory hormonal response to hypoglycemia is blunted in congenital hyperinsulinism. Diabetes 2005;54:2946-2951.